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Abstract 0 Drugs are absorbed after oral administration as a conse-
quence of a complex array of interactions between the drug, its formulation,
and the gastrointestinal (GI) tract. The presence of food within the GI
tract impacts significantly on transit profiles, pH, and its solubilization
capacity. Consequently, food would be expected to affect the absorption
of co-administered drugs when their physicochemical properties are
sensitive to these changes. The physicochemical basis by which ingested
food/lipids induce changes in the GI tract and influence drug absorption
are reviewed. The process of lipid digestion is briefly reviewed and
considered in the context of the absorption of poorly water-soluble drugs.
The effect of food on GI pH is reviewed in terms of location (stomach,
upper and lower small intestine) and the temporal relationship between
pH and drug absorption. Case studies are presented in which postprandial
changes in bioavailability are rationalized in terms of the sensitivity of
the physicochemical properties of the administered drug to the altered
GI environment.
Introduction
The presence of food within the gastrointestinal (GI) tract
can markedly alter the oral bioavailability of drugs1,2 via
changes in the rate and/or extent of absorption,3-6 presystemic
metabolism,7,8 and systemic drug clearance.9-11 These changes
can lead to variations in efficacy and toxicity profiles because
medications are often taken under conditions of varying food
and fluid intake. Although knowledge of such interactions is
important from developmental, clinical, and regulatory stand-
points, the effect of food on bioavailability has often been
addressed in a largely phenomenological manner.
The presence of food within the GI tract was historically
regarded as a barrier to absorption, leading to suggestions
that drugs should be taken on an empty stomach when
possible.12,13 However, it is currently accepted that the
interaction between food and drugs should be examined on
an individual basis.14-16 The character and magnitude of the
effect of food on bioavailability is a function of the drug, the
dose, the nature of the formulation, the size and composition
of the food, and the temporal relationship between food
ingestion and drug administration.16
Notwithstanding the physical and chemical interactions
that may occur between drugs and specific food compo-
nents,8,17,18 altered postprandial absorption is generally a
function of the changes associated with conversion from the
fasted to the fed state. Changes due to (i) secretion of gastric
acid and bile and pancreatic fluids, (ii) modification of gastric
and intestinal motility patterns, and (iii) alterations in visceral
blood and lymph flow have the most significant impact on
absorption.
Algorithms for estimating drug absorption often involve
consideration of the dose, aqueous solubility, and drug perme-
ability. Amidon et al.19-21 developed useful predictive rela-
tionships for absorption in the fasted state employing physical
model approaches for drugs with a “reasonable degree” of
water solubility (considered in the context of the administered
dose). However, the predictive aspects of postprandial bio-
availability is more problematic.
The review of the literature presented here demonstrates
that there is often a physicochemical basis to altered bioavail-
ability when drugs are administered postprandially. We
briefly review the major physiological changes that occur in
the postprandial GI environment to provide a framework for
examining effects of food on bioavailability. We focus on the
wide ranging effects of stimulation of the lipid digestion
cascade (increased drug wetting and solubilization, recruit-
ment of intestinal lymph, and effects on GI motility) and
modulation of GI pH (degree of ionization, solubility) on drug
absorption. The effect of food on bioavailability frommodified-
release formulations is not considered because we specificallyX Abstract published in Advance ACS Abstracts, January 15, 1997.
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address intrinsic absorption-related factors rather than ex-
trinsic dose form effects.
Lipids And The Post-Prandial Intestinal
Environment
Digestion and Absorption of LipidssLipids are a major
constituent of food that can influence drug absorption. In-
gested lipid decreases gastric motility, and the presence of
lipid digestion products within the upper small intestine
induces secretion of biliary and pancreatic fluids that dra-
matically alter the luminal environment. The digestion and
absorption of lipids has received most attention in the
nutritional and physiology literature because of the funda-
mental role it plays in health maintenance.22-26
Lipid digestion is the result of three sequential processes
involving (i) dispersion of fat globules into a coarse emulsion
of high surface area, (ii) enzymatic hydrolysis of the fatty acid
glyceryl esters (primarily triglyceride lipid), and (iii) dispersion
of the products of lipid digestion into an absorbable form.27
Lingual lipase secreted by the salivary gland and gastric
lipase secreted by the gastric mucosa are responsible for
initiating hydrolysis of ingested triglyceride (TG) to the
corresponding diglyceride (DG) and fatty acid (FA) within the
stomach. Liberation of these amphiphilic lipid digestion
products, in combination with the shear produced by antral
contraction and gastric emptying, facilitates formation of a
crude emulsion that empties into the duodenum. The pres-
ence of lipid in the duodenum stimulates secretion of bile salts,
biliary lipids, and pancreatic juice. Biliary lipids adsorb to
the surface of the crude emulsion, stabilizing it and further
reducing droplet size.27 Subsequently, the majority of TG
hydrolysis occurs under the action of pancreatic lipase, which
requires the presence of colipase to be active in the presence
of bile salts. It is an interfacial enzyme that acts at the
surface of the emulsified TG droplets to quantitatively produce
the corresponding 2-monoglyceride (MG) and two FA.28,29
These digestion products are effective emulsifying agents, and
because FA promotes binding of the lipase/colipase complex
to the emulsion surface,30,31 the lipolytic process is essentially
selfpromoting. Phospholipids are hydrolyzed to the corre-
sponding lysophospholipids by phospholipase A2 prior to
absorption, and in quantitative terms, the majority of phos-
pholipid reaches the GI tract via biliary secretion with only
modest inputs from dietary sources.
In the early 1960s, Hofmann and Borgstrom32,33 subjected
human postprandial intestinal contents to ultracentrifugation-
based separation and determined that the in vivo products of
lipid digestion partitioned between an oily phase and a
solubilized bile salt mixed micellar phase. More recently,
Carey et al.34,35 identified the presence of unilamellar vesicles
in equilibrium with bile salt mixed micelles from aspirates of
human postprandial intestinal fluid. Current understanding
suggests that during lipolysis, digestion products “pinch off”
from the surface of the TG/DG emulsion to produce liquid
crystalline structures, which then form multilamellar and
unilamellar structures in the presence of sufficient bile salt
concentrations. The intestinal mixed micellar phase described
by Hofmann and Borgstrom is now thought to exist in a two-
phase equilibrium system with unilamellar lipid vesicles.26,34,35
The absorptive membrane of the enterocyte is separated
from the bulk aqueous phase of intestinal contents by a poorly
mixed unstirred water layer (UWL) that constitutes a barrier
to absorption of poorly water-soluble lipid digestion products.
Although the specific absorption mechanisms have not been
elucidated, the common role of the mixed micellar phase in
solubilizing poorly water-soluble lipid digestion products and
providing a concentration gradient for absorption of mono-
meric lipids is generally accepted.36-38 Micelles are not
absorbed intact,39,40 and lipids are thought to be absorbed from
a monomolecular intermicellar phase.37 In support of the
importance of the intermicellar phase, concentrations of
cholesterol several times higher than the saturated aqueous
solubility can be achieved in the intermicellar environ-
ment.41,42 The dissociation of monomolecular lipid from the
mixed micellar phase prior to absorption may be stimulated
by a microclimate of lower pH associated with the absorptive
site.43-45 Reports have described the existence of an entero-
cyte-based carrier system, termed the microvillus membrane
fatty acid binding protein, which in tandem with passive
diffusion may be responsible for the uptake of FA and other
lipid substrates into the enterocyte.46,47 Although evidence
is mounting to suggest that uptake of lipid digestion products
may not be entirely via simple diffusion, further work is
required to clearly define the factors and processes involved.
The majority of absorbed long-chain FA and MG migrates
to the endoplasmic reticulum where re-esterification and
assembly into lipoproteins occurs prior to secretion into
lymph.48 As a general guide, FA of chain length <12 carbons
(∼10% of dietary lipid) are absorbed via the portal blood,49
whereas FA with longer chain lengths are reesterified and
transported via intestinal lymph. However, the chain length
dependence of portal or lymphatic transport is less clear cut
than this “rule of thumb” as there are reports of lymphatic
transport of medium-chain FA and portal blood absorption of
long-chain FA.50,51
Bile and Bile Salt MicellessAn average composition of
human gall bladder bile is ∼84% water, 11.5% bile salts, 3%
lecithin, 0.5% cholesterol, and 1% other components, such as
bile pigments, inorganic ions, and protein.52 In response to
the intestinal presence of digestion products (especially lipid
digestion products), cholecystokinin-mediated contraction of
the gall bladder and relaxation of the sphincter of Oddi leads
to expulsion of bile, with peak flow occurring ∼30 min after
meal ingestion. Although variable, typical bile salt concentra-
tions in the fasted intestine are 4-6 mM compared with
postprandial levels of 10-20 mM.53 Approximately 40% of
bile salts are conjugates of cholic acid, 40% are conjugates of
chenodeoxycholic acid, and the remaining 20% are conjugates
of deoxycholic acid.53,54
Bile salts form polymolecular aggregates, the structural
characteristics of which are dependent on solution pH, tem-
perature, compositional distribution of other bile acids, and
the presence of biliary lipids and lipid digestion products.55
Although the formation of bile salt aggregates is termed
micellization, bile salt aggregation is more gradual than
observed for synthetic surfactants, and the aggregation
number is much less. Carey and Small56 described bile salts
forming either primary or secondary micelles. Primary bile
salt micelles have aggregation numbers up to 10 and are
formed via hydrophobic interactions, whereas secondary mi-
celles are formed via hydrogen bonding interactions of the
primary micellar structures.
The chemistry of mixed bile salt micelles is dictated by the
structural inclusion of lecithin, lysolecithin, and the products
of lipid digestion that decreases the critical micelle concentra-
tion (cmc), increases the size of the micelle, and significantly
increases solubilization capacity. For example, the inclusion
of swelling amphiphiles such as lecithin and MG decreases
the cmc of mixed micellar systems to values <1 mM.56-59
Therefore, it is likely that the cmc of mixed bile salt micelles
is surpassed even in the fasted state. The secretion of bile in
response to food is responsible for an overall increase in the
solubilizing capacity of the GI tract by increasing micelle
numbers rather than increasing bile salt levels to suprami-
cellar concentrations.
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The Role of Bile in Drug Dissolution and
Solubilization
The presence of bile may improve the bioavailability of
poorly water soluble drugs by enhancing the rate of dissolution
and/or solubility. An increase in the rate of dissolution can
occur via (i) a decrease in the interfacial energy barrier
between solid drug and the dissolution medium (via enhanced
wetting), leading to an effective increase in surface area, or
(ii) an increase in solubility via micellar solubilization.
However, a consequence of drug solubilization within the bile
salt micelle is a decrease in the apparent diffusion coefficient
of the drug. In general, enhanced wetting predominates at
bile salt concentrations below the cmc, whereas enhanced
solubility is dominant at concentrations above the cmc.60 It
is important to note that changes in the dissolution rate of
poorly water-soluble drugs due to wetting or solubilization is
compound dependent due to the specificity of the interactions
associated with these processes.56,58,59
Poorly water-soluble drugs partition between the postpran-
dial multilamellar and unilamellar structures, emulsion
droplets, and the mixed micellar phase. The character of
these colloidal phases is controlled by the relative concentra-
tions of bile salts, biliary lipids, and lipid digestion products
and is therefore continually changing. As time progresses
after ingestion of a meal and the relative proportions of the
high lipid load emulsion droplets and multilamellar vesicles
decreases relative to the end stage mixed micelle and unila-
mellar vesicles, the nature of the available “dissolution media”
changes correspondingly. Therefore, dissolution is subject to
change not only as a function of the fed/fasted cycle but also
the kinetics of lipid digestion.
Solubility and WettingsThe effect of bile salt solubili-
zation has been studied for many drugs; for example,
griseofulvin,61-63 danazol,58 digoxin,64 diethylstilbestrol,65 di-
azepam,66 halofantrine,67 leucotriene antagonists,68 and gem-
fibrozil.69 Typically, solubility may increase 0.2-2 orders of
magnitude in representative postprandial simple micellar
systems compared with buffer control. The further addition
of lecithin and/or lipid digestion products to simple bile salt
micelles does not necessarily lead to further increases in
solubility or dissolution rate.
Bile salts can increase the rate of dissolution via enhanced
wetting in a compound-specific manner. For example, Miyaza-
ki et al.71,72 suggested that the enhanced dissolution of
phenylbutazone in simple bile salt solutions was mediated via
increased wetting, whereas micellar solubilization was re-
sponsible for improved dissolution of indomethacin. Bakat-
selou et al.58 investigated the powder dissolution rate of five
steroids in sodium taurocholate (NaTC) solutions representa-
tive of fasted and fed states (3.75 and 15 mM NaTC,
respectively). The increased dissolution under simulated fed
state conditions for four of the five steroids (log P values 1.01-
1.94; viz., triamcinolone, hydrocortisone, dexamethasone, and
betamethasone) was primarily augmented by improved wet-
ting. In contrast, the increased dissolution of danazol (log P
4.5) was primarily mediated via solubilization. Subsequent
studies examined the dissolution of hydrocortisone in simple
and mixed micellar systems and determined that wetting was
the predominant factor that improved the rate of dissolution
in simple bile salt micelles, whereas solubilization appeared
to be major mechanism for improving dissolution in the mixed
micellar systems.59 The solubility and dissolution of choles-
terol in bile salts has been extensively studied by Higuchi et
al.73-80 Although these studies were targeted towards un-
derstanding gallstone dissolution, they provide valuable data
regarding the dissolution of highly lipophilic compounds.
Dissolution was facilitated by simple bile salt micelles,
although addition of lecithin to form mixed micelles markedly
decreased dissolution in spite of improved solubility. Subse-
quent studies demonstrated that dissolution in mixed micelles
was not diffusion controlled but limited by an electrostatic
barrier at the dissolving interface.77,80 Although cholesterol
is an extreme example, surface-based reactions may become
important for extremely lipophilic compounds with minimal
aqueous solubility.
Not all interactions of poorly water-soluble drugs with bile
salts lead to increased solubilization. Examples where the
formation of insoluble, poorly absorbed drug-bile salt com-
plexes leads to decreased bioavailability include, among
others, pafenolol,81 tubocurarine,82 neomycin and kanamycin,83
and various large molecular weight antibiotics.84 Related
situations where poorly absorbed complexes are formed
between the drug and components of the ingested meal include
the well-known examples of tetracyline85 and penicillamine.86
These examples of food-affected bioavailability are outside the
scope of this review and reviews by Welling15,16 should be
consulted for further detail.
The lack of predictability of solubility and dissolution rate
of poorly water-soluble drugs in bile salt systems indicates
the compound-specific nature of the interaction. Additionally,
there is a likely differential between the sensitivity of the
kinetic processes (rate of wetting and rate of dissolution) and
the equilibrium processes (solubility and composition of the
drug containing micelle) in the micellar components. Figure
1 is a schematic representation that summarises the various
steps involved in lipid digestion, the formation of the various
micellar phases, and the influence that the postprandial GI
environment can have on the dissolution and solubilization
of coadministered drugs.
Absorption, Permeability, and the Postprandial
Intestine
The constituents of the mixed micellar phase impact on the
intestinal permeability of poorly water-soluble drugs via three
major processes. First, lipid digestion products and bile salts
characteristic of the fed state may alter the intrinsic perme-
ability of the intestinal membrane leading to increased
penetration via paracellular or transcellular routes. Second,
solubilization of poorly water-soluble drugs within bile salt
micelles may facilitate diffusion through the UWL leading to
increased absorption. Third, and conversely, solubilization
may decrease the intermicellar “free” fraction of drug that
could lead to a decrease in absorption. These divergent effects
are the basis for the often contradictory reports concerning
drug absorption when drugs are administered as solubilized
systems. These issues are not new, and the points raised in
a 1970 review by Gibaldi and Feldman87 are as relevant today
as when the article first appeared.
The permeability enhancing abilities of bile salts, FA, and
MG in the intestinal tract is well known.88-93 When consider-
ing these naturally occurring permeability enhancers, it is
apparent that the intestinal mucosa is frequently subjected
to dietary-induced damage and that mechanisms have evolved
for rapid repair.94 Kvietys et al.95 studied the role of lipolytic
digestion products in causing mucosal injury and demon-
strated that perfusion of emulsified oleic acid through the rat
small intestine induced damage to villus tips, although the
damage was rapidly repaired within 1 h of stopping the
perfusion. These data led to the conclusion that damage to
the intestinal epithelium by the products of lipid digestion
may be a common occurrence during the normal digestive and
absorptive processes.
The following representative examples describe the range
of effects that lipid digestion products and bile salts may have
on drug absorption when studied using in situ methods.
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However, caution must be exercised when extrapolating data
from in situ absorption/perfusion studies to intact animals
where the physiological and compositional characteristics of
the GI tract are constantly changing. The effect of bile salts
on the intestinal absorption of model hydrophilic (paracetamol
and theophylline) and lipophilic drugs (griseofulvin, keta-
conazole, and dantrolene) was studied by Poelma et al.96,97
using a rat in situ intestinal perfusion technique. Simple or
mixed bile salt micelles had no effect on absorption of the
hydrophilic drugs, leading to the conclusion that bile salt
micelles had minimal effect on the intrinsic barrier function
of either the UWL or the intestinal membrane. In contrast,
simple or mixed bile salt micelles reduced the absorption of
the lipophilic drugs, which in the case of griseofulvin was
correlated with a reduction in the free fraction of drug due to
solubilization. Similar profiles have been reported by Segura-
Bono et al.98 who, in the latest of a series of reports,99-102
described a decrease in the rate of absorption of a range of
phenylalkylcarboxylic acids solubilized in simple or mixed
micelles.
In contrast to the data just presented, where solubilization
decreased absorption, numerous reports have described en-
hanced intestinal absorption from bile salt-solubilized sys-
tems. For example, O’Reilly et al.103,104 described enhanced
absorption of a highly lipophilic rimnophenazine derivative
in the presence of high concentration simple or mixed bile salt
micelles. The tacit assumption when the absorption of lipo-
philic compounds is improved with bile salt micelles is that
transcellular absorption is enhanced. In this study, the
absorption of a poorly absorbed hydrophilic marker (PEG
4000)105 was simultaneously assessed. At bile salt concentra-
tions >40 mM, there was a significant increase in the
permeability of PEG 4000, whereas concentrations of 80 mM
were required to enhance absorption of the lipophilic rim-
nophenazine derivative. This difference suggested that the
enhanced permeability of PEG 4000 was due to a change in
the paracellular permeability of the membrane mediated by
the bile salt solutions. Similar observations were made with
streptomycin and gentomycin for which mixed micellar sys-
tems markedly enhanced absorption.106 Subsequent studies
demonstrated that the enhanced absorption was due to an
alteration of the membrane permeability by the lipid compo-
nent of the micelles,107,108 with the high aqueous solubility of
streptomycin and gentomycin most likely favoring the para-
cellular route of absorption.
In summary, solubilization in the terminal phases of lipid
digestion, notably the intestinal micellar phases, can have a
considerable effect on the absorption of poorly water-soluble
drugs. Consequently, the potentially large increase in dis-
solution and solubilization of such compounds in the post-
prandial environment is the most likely basis for enhanced
absorption.
Altered GI Transit Profiles
The products of lipid digestion delay gastric emptying,109,110
and most pharmaceutical attention has focussed on the
relationship between gastric emptying, food ingestion, and the
handling of different dosage forms.111-115 Generally, delayed
gastric emptying has the potential to increase absorption of
poorly water-soluble drugs by increasing the time available
for dissolution. For acid-labile and ionizable drugs, coadmin-
istration with food increases the residence time in the acidic
environment, which impacts on solubility and stability issues.
However, the increase in stomach pH in response to food
ingestion makes it difficult to predict the likely overall effect
on bioavailability, and these issues are addressed in a
subsequent section.
Intestinal Lymphatic Drug Transport
The intestinal lymphatics are a specialized transport path
for highly lipophilic drugs, lipids, and lipidic derivatives. The
physiological, biopharmaceutic, and formulation-related fac-
tors that influence lymphatic drug transport have been
recently reviewed.116-119 Once a drug has gained access to
the intestinal lymphatics (in association with intestinal lipo-
proteins), it drains into the thoracic lymph duct that empties
into the systemic circulation at the junction of the left internal
jugular and left subclavian veins. Therefore, lymphatic
transport can bypass hepatic first-pass metabolism and
thereby increase bioavailability, and target drugs to regions
of the body directly supplied by the mesenteric lymphatics.
Examples of compounds that are transported (to varying
degrees) by the intestinal lymphatics include cyclosporin,120
naftifine,121 probucol,122 mepitiostane,123-124 lipophilic vita-
mins and vitamin derivatives,125 halofantrine,126 xenobiotics
such as DDT and related analogs,127-129 benzo-(a)-pyrene,130
and numerous lipophilic prodrugs.118
Compounds transported via the intestinal lymphatics are
generally associated with the lipid TG core of chylomicrons
that are formed by the enterocyte. The resynthesis of TG to
Figure 1sSchematic representation of the processing involved with the digestion
of lipids, the formation of the various colloidal phases present within the postprandial
intestine, and the subsequent absorption of the lipid digestion products (and drugs)
by the enterocyte. Poorly water-soluble drugs that are coadministered with either
food or lipid-based formulations can benefit from the processes involved with
lipid digestion through enhanced wetting and solubilization facilitated by the
conditions present in the postprandial intestine. Absorption is generally passive
in nature, with the drug and lipid digestion products absorbed from the intermicellar
phase.
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support chylomicron formation occurs via either of two
pathways, with the major and most energy-efficient path being
the direct and sequential acetylation of absorbed 2-MG with
activated FA to form the corresponding DG and TG lipids.
The resynthesized TG is then progressively shunted through
intracellular organelles where the surface is stabilized by
addition of phospholipids and apoproteins. The obligatory
dependence of chylomicron formation on the phospholipid and
apoprotein coating, and their ordered and sequential as-
sembly, have been the subject of various reviews.22,23,26 Phos-
pholipids, which cover as much as 80% of the chylomicron
surface,131 are formed in the enterocyte via reesterification of
absorbed lysophospholipids with an activated long-chain FA.
The rate of fluid transport in the intestinal lymphatics is
∼0.2% (v/v) compared with portal blood.132 Consequently,
there is minimal opportunity for the selective lymphatic
transport of small molecular weight, water-soluble drugs
where absorption via the portal blood or lymph is largely
governed by the relative rates of fluid flow. However, as-
sociation of lipophilic drugs with the TG core of chylomicrons
can provide a means for attaining high lymphatic drug
concentrations and thereby contribute to bioavailability.
The major factors for lymphatic transport to be a significant
contributor to bioavailability include coadministration of a
lipid source, metabolic stability, and sufficiently high lipo-
philicity. In terms of a “ball park” estimate, the log P of a
candidate drug needs to be >5, with a TG solubility of at least
50 mg/mL, before lymphatic transport is likely be a major
contributor to bioavailability.116,133 Therefore, although lym-
phatic transport is a biological process, the potential for it to
contribute to oral bioavailability can be reasonably estimated
from consideration of the relevant physicochemical properties
of the drug.
A common difficulty in assessing the role of lymph transport
in enhanced postprandial absorption arises because conclu-
sions are often indirectly drawn from consideration of plasma
concentration-time profiles. The physicochemical properties
of the drug should always be considered when estimating the
potential contribution of lymphatic transport to enhanced
postprandial bioavailability, and animal studies are typically
required to confirm lymphatic transport.132,134
Case Studies: Dissolution, Solubilization, and
Lymphatic Transport
Notwithstanding the potential nonspecific binding of drugs
to constituent parts of a meal, the effect of lipids on postpran-
dial drug absorption can often be assessed by considering
enhanced dissolution/solubilization, modulation of gastric
emptying, and stimulation of lymphatic transport. The fol-
lowing case studies are selected examples for which enhanced
postprandial oral bioavailability has been assessed in this
manner (Table 1).
GriseofulvinsThe classic example of enhanced postpran-
dial bioavailability is griseofulvin.135 Bates et al.61-63 dem-
onstrated that the enhanced solubility and dissolution of
griseofulvin in supramicellar concentrations of bile salts was
the primary basis for the enhanced absorption. Recently, it
was demonstrated in vitro that although addition of lecithin
to NaC micelles increased the solubility of griseofulvin up to
5-fold, only marginal effects were observed on dissolution
rate.136 The lack of a concomitant increase in dissolution rate
with increasing solubility was ascribed to a progressive
decrease in the diffusion coefficient of the mixed micelle due
to a lecithin concentration-dependent increase in its size.
Within the lecithin and bile salt concentration range studied,
the coexistence of simple and mixed micelles impacted on the
relative partitioning of griseofulvin between these micellar
structures, that is, increasing amounts of drug solubilized in
the mixed micelles as the molar ratio of lecithin to bile salt
increased. However, the concentration of “free” drug in the
various bile salt/lecithin solutions remained relatively con-
stant at ∼10% of the total concentration.
DanazolsDanazol is a high-dose, poorly water-soluble
steroid that exhibits highly variable oral bioavailability in the
fasted state. The oral bioavailability from a capsule formula-
tion increased 3-fold when administered 30 min after ingestion
of a fatty meal (Table 2).137 The improved absorption after
postprandial administration of the capsule was attributed, in
part, to increased dissolution and improved solubilization
within the postprandial GI contents. When the same dose of
danazol was administered as a MG-based lipid emulsion to
either fed or fasted subjects, the plasma levels were similar
to those achieved after postprandial administration of the
capsule formulation (Table 2). The apparently optimal per-
formance of the MG-based emulsion formulation in the fasted
subjects was ascribed to the triggering of an effective “post-
prandial” GI environment.
In vitro studies demonstrated a 10-fold increase in the
solubility of danazol in 15 mM NaTC compared with buffer
Table 1sExamples of Increased Postprandial Oral Bioavailability and the Likely Basis for the Increased Absorption
Compound Increase in Bioavailability Basis for Food Effect Ref
Griseofulvin 3−5-fold (humans) v solubilization f portal blood transport 62, 63, 135
Danazol 4-fold (humans) v solubilization f portal blood transport 58, 137
R-Tocopheryl 5-fold (dogs) v solubilization f portal blood and lymph 132, 140
nicotinate 28-fold (humans) transport
Halofantrine 10-fold (dogs) v solubilization f portal blood transport 67, 143
3-fold (humans) possible lymph transport
Atovaquone 3−5-fold (humans) v solubilization f portal blood transport 145
Retinoic acid 2−5-fold (humans) likely v solubilization f portal blood transport 147, 148
derivatives possible lymph transport
Table 2sEffect of Food on the Oral Bioavailability of Danazol and the
Effect of Bile Salt Concentration on the In Vitro Equilibrium Solubility
and Initial Dissolution Rate of Danazol a
Bioavailability Parametera,b
Administration Plasma AUC (ng h/mL) Cmax (ng/mL)
Fasted Capsule 204 ± 125 37 ± 16
Fed capsule 639 ± 259 101 ± 42
Fasted MG emulsion 779 ± 189 155 ± 55
Fed MG emulsion 844 ± 194 126 ± 56
Physicochemical Parameters




a Results were determined after administration of 100 mg of danazol to human
subjects (n ) 11) and are expressed as mean ± SD. b The data are from refs 58
and 137. c DR, Dissolution rate.
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control (Table 2), and 3- and 10-fold improvements in dis-
solution under representative postprandial simple58 and mixed
micellar138 solutions, respectively. The magnitude of the
increase in the dissolution rate and solubility of danazol at
bile salt concentrations >5 mM is consistent with the in-
creased postprandial bioavailability. Consideration of contact
angle measurements in the context of the solubility and
dissolution data indicated that solubilization, rather than
enhanced wetting, was the primary basis for increased dis-
solution of danazol.58
r-Tocopheryl NicotinatesThe fat-soluble vitamins, in-
cluding R-tocopherol, have poor oral bioavailability and largely
gain access to the systematic circulation via the intestinal
lymphatics. As R-tocopherol is unstable due to oxidation of
the phenol group, numerous prodrug strategies have been
employed to combat both its low bioavailability and poor
stability.139-142 Hasegawa et al.140 studied the effect of food
on the bioavailability of a nicotinate prodrug of vitamin E (R-
tocopheryl nicotinate) in beagles and humans. When R-toco-
pheryl nicotinate was administered postprandially to beagles,
there was a 5-fold enhancement in bioavailability compared
with administration in the fasted state. In humans, the
bioavailability of R-tocopheryl nicotinate improved 28-fold
when administered in the fed state. These improvements in
bioavailability of R-tocopheryl nicotinate after postprandial
administration were a function of both improved dissolution
and solubilization, which improved absorption into the portal
blood, as well as recruitment of intestinal lymphatic transport
as a contributor to oral bioavailability.118,132
HalofantrinesHalofantrine hydrochloride (Hf‚HCl) is a
highly lipophilic phenanthrene derivative (calc. log P, 8.5) used
for the treatment of drug-resistant malaria. When adminis-
tered postprandially, bioavailability increased threefold in
humans,143 and 10-fold in beagles (Table 3).67 Studies con-
ducted in lymph-fistulated rats demonstrated 5% transport,144
indicating that the increased postprandial bioavailability was
unlikely to be a function of lymphatic transport.
In vitro solubility and dissolution studies of Hf‚HCl indi-
cated that these parameters were very sensitive to bile salt
concentration and micellar composition. For example, the
solubility of Hf‚HCl in simple bile salt micelles representative
of the fasted state (3.75 mM NaTC) was 2.1 µg/mL. In
conditions representative of the fed state, such as 15 mM
NaTC mixed micelles, the solubility increased to >2000 µg/
mL.67 The solubility and dissolution rate of Hf‚HCl as a
function of bile salt concentration are shown in Table 3. There
was a marked increase in these parameters at post-cmc bile
salt concentrations, with the magnitude of the increase being
much larger than observed with danazol. Because of the
similarity between the solubility and dissolution rate profiles,
it is likely that enhanced solubilization, rather than wetting,
was the basis for the increased dissolution of Hf‚HCl. These
data indicate that the increased postprandial absorption of
Hf‚HCl is consistent with the dramatically enhanced dissolu-
tion and solubilization of the compound in the presence of
mixed bile salt micelles.
AtovaquonesAtovaquone is a highly lipophilic antiproto-
zoal drug that is slowly and irregular absorbed after oral
administration in the fasted state. Administration of a tablet
formulation with either a low or high fat breakfast improved
bioavailability 3.3-fold and 5.3-fold, respectively.145 The aque-
ous solubility of atovaquone is <0.1 µg/mL, which increased
to ∼100 µg/mL under simulated postprandial conditions. The
potential lymphatic transport of atovaquone in the fed state
was investigated by isolating chylomicrons from the plasma
and analyzing for the presence of drug. This is a useful
approach for noninvasively identifying the occurrence of
intestinal lymphatic transport in humans, although the rapid
plasma clearance of chylomicrons and lipophilic drugs requires
validation on a case-by-case basis. Atovaquone was not
detected with this approach, suggesting that lymphatic trans-
port was not a contributing postprandial absorption pathway.
These data indicate that the basis for the enhanced absorption
of atovaquone was most likely the enhanced solubilization
capacity of the postprandial GI environment leading to
enhanced portal blood absorption.
Retinoic Acid DerivativessEtretinate is an orally active
retinoid that undergoes first pass deesterification to form
etretin, which subsequently isomerizes to form isoetretin.146
The oral bioavailability of etretinate increased 3-5-fold when
administered with a high fat meal or milk compared with
fasted administration.146,147 The amount of metabolite formed
(defined by the area under the metabolite plasma concentra-
tion-time curve) was unchanged after administration of
parent compound in either the fed or fasted state, indicating
that coadministration of etretinate with food significantly
increased the amount of parent drug absorbed, but appeared
to reduce the extent of metabolism. Due to the structural
similarity with Vitamin A, it was speculated that solubiliza-
tion of etretinate in the postprandial intestinal environment
may have facilitated both portal blood absorption and lym-
phatic transport. Isotretinoin is another orally active retinoid
where bioavailability is also significantly enhanced when
administered postprandially.148
Predictive Approaches to Assessing
Lipid-Enhanced Bioavailability
Physicochemical properties, such as solubility in aqueous,
organic and lipidic solvents, and octanol/water partition
coefficients, are a useful starting point in identifying possible
absorption problems when used in combination with various
absorption models.19-21 Analysis of these data can often
identify whether absorption of a poorly water-soluble drug
may be sensitive to the changes that occur in the postprandial
GI tract. (Recent evidence has identified oxidative metabolism
in intestinal villous tips and a P-glycoprotein countertransport
process as potential contributors to the poor oral bioavailabil-
ity of cyclosporine, which is poorly water soluble.150,151 Fur-
thermore, it appears that some lipidic derivatives may inhibit
the P-glycoprotein countertransport system, thereby enhanc-
ing the bioavailability of compounds subject to this efflux
system.152,153 Although further data and examples are re-
quired before these findings can be more widely assessed, they
offer an interesting new perspective when assessing the
limited bioavailability of poorly water-soluble drugs.)
Table 3sOral Bioavailability Parameters for Halofantrine HCl After
Administration to Either Fasted or Fed Healthy Human Subjects and
Fasted or Fed Beagle Dogs and the Effect of Bile Salt Concentration on
the In Vitro Equilibrium Solubility and Intrinsic Dissolution Rate of
Halofantrine HCl
Human Subjectsb Beagle Dogsc
Bioavailability
Parametera Fasted Fed Fasted Fed
Plasma AUC (mg h/L) 3.9 ± 2.6 11.3 ± 3.5 4.2 ± 2.7 51.5 ± 9.4
Cmax (ng/mL) 184 ± 115 1218 ± 464 275 ± 156 5540 ± 2107
Physicochemical Parameter
NaTC Conc Solubility (µg/mL) Intrinsic DRd (µg/s/cm2)
3.75 mM 2.1 0.0061
3.75 mM + lecithine 37.3 0.0722
15 mM + lecithin 2252 1.2243
30 mM + lecithin 4513 2.2769
a Data are presented as mean ± SD and are from refs 67 and 143. b n ) 6.
c n ) 3. d DR, Dissolution rate. e NaTC: lecithin molar ratio of 4:1.
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The solubility and dissolution rate of drugs can be readily
determined as a function of bile salt concentration,149 and
these results can then be equated with the likely fasted and
fed conditions that occur in vivo. These measurements are
typically conducted with a single bile salt, such as NaTC or
NaGC, although Staggers et al.34 suggested a mixture of 10
bile salts to more accurately represent the in vivo situation.
As biliary lipids and lipid digestion products are required to
form mixed micellar systems, there is also merit in examining
these more complex micellar systems. However, financial and
logistical constraints limit the number of components used
in such experiments, particularly for dissolution media for
which large volumes are often required.
The development of lipid digestion models is an area
requiring further research because these models offer a means
for following the passage of lipophilic drugs through the
various phases associated with lipid digestion. Reports exist
where in vitro lipid digestion models154,155 have been used to
assess the rate and extent of transfer of drugs from a
prospective formulation, through the respective colloidal
phases, to the final mixed micellar phase.156 It has been
proposed that the rate of transfer may be a crucial rate-
determining step in the absorption of highly lipophilic drugs,
particularly from lipid-based formulations.156
There are various animal models available for the confir-
mation of intestinal lymphatic transport134,157; however, the
best first step is estimation of the potential for transport from
consideration of the partition coefficient and lipid solubility
of the drugs. If such calculations indicate that lymphatic
transport may be a contributor to oral bioavailability, then
further confirmatory experiments should be undertaken.
These studies are especially important to identify optimal
lipid-based formulations for such drugs.
The Effect of pH on Drug Absorption
As aspects of drug absorption and dosage form performance
are sensitive to the pH environment of the GI tract, postpran-
dial changes in GI pH values can influence drug absorption.
The basal values and temporal changes that occur in GI pH
profiles and the physicochemical basis by which these altered
pH profiles can impact on drug absorption and bioavailability
are now described.
Basal Gastric Acid and Pancreatic Bicarbonate
SecretionsThe human stomach contains approximately one
billion parietal cells that produce HCl at a concentration of
∼160 mEq/L.158 In the fasted state, basal gastric acid secre-
tion is∼2-4 mmoL/h in men and slightly lower in women.159,160
The exocrine secretions of the pancreas consist of a high-
volume aqueous secretion containing bicarbonate ion and a
low-volume aqueous secretion containing digestive enzymes.
There is ∼1 L of pancreatic fluid secreted daily into the
duodenum, with the alkaline component ranging between 0.2
and 0.8 L.158 Basal secretion of bicarbonate is 1-2% of the
maximal secretory rate, which can be induced by exogenous
administration of secretin.161 A cyclical pattern of basal
pancreatic secretion was demonstrated in humans and con-
sisted of brief increases in bicarbonate secretion every 1-2 h
that were associated with the interdigestive migrating motor
complex.162-164 The flow rate typically increased from 0.3 mL/
min in the resting state to 4.0 mL/min during stimulation.165
When the flow rate was at a lower value of 0.6 mL/min, the
concentration of bicarbonate was ∼25 mEq/L, resulting in a
secretion rate of ∼1 mEq/h.166
Fasting Upper GI pH in Young Healthy Subjectss
Fasting gastric pH has been well studied, and the generally
accepted value is between 1.5 and 2.167-170 In a Heidelberg
capsule study of 24 young healthy volunteers, Dressman et
al.170 observed a median fasted gastric pH of 1.7 [inter-quartile
range (IQR), 1.4-2.1]. During the 1 h observation period
employed in the study, episodes of elevated gastric pH were
recorded in the majority of subjects. For example, the fasting
pH was <2 for 68% of the time and <3 for 90% of the time,
whereas pH values >4 were evident 6% of the time, with
readings as high as pH 6 rarely observed.
The fasting pH profile of the duodenum has been most
extensively measured in the duodenal bulb,171-174 with the
variability in reported values (pH 2.4 to 6.8) being due to the
wide temporal and positional fluctuations in this area of the
duodenum. A smaller number of studies have investigated
the pH in the mid to distal region of the duodenum,167,170,174,175
with a median pH in the mid-distal duodenum of young
healthy volunteers reported to be 6.1 (IQR, 5.8-6.5).170
The fasting pH of the jejunum is typically reported to range
between 6 and 7.176 However, Ovesen et al.174 determined the
fasting pH in the proximal jejunum to range between 5.9 and
6.2, Watson et al.172 described a range of jejunal pH values
between 3.1 and 6.5, and Zentler-Munro et al.178 reported the
fasting pH to be <5.0 for 17% of the time. Reported values of
pH in the distal ileum in the fasted state range between 6.5
and 8.171,179 Reported regional intestinal pH values in healthy
human subjects in preprandial or postprandial states are
compiled in Table 4.
Variation in Upper GI pH ValuessGastric pH is sensi-
tive to increasing age, pathological conditions and drug-
induced changes. Although the majority of elderly people
exhibit gastric pH profiles similar to younger people, ∼10-
20% of the elderly population exhibit either diminished
(hypochlorhydria) or no gastric acid secretion (achlorhydria),
leading to basal gastric pH values >5.0.181-184 In a recent
study of 79 healthy elderly subjects (71 ( 5 years), the
observed median fasting gastric pH was 1.3 (IQR, 1.1-1.6),
although in five achlorhydric subjects, the median fasting pH
was as high as 7.1.185 Duodenal pH was also slightly higher
in healthy elderly subjects compared with younger subjects.
The overall median fasting duodenal pH of healthy subjects
was 6.5 (IQR, 6.2-6.7), whereas in achlorhydric subjects it
was 6.8.185
Pathological conditions in which there is a decrease in
gastric acid secretion leading to elevated gastric pH values
include pernicious anemia184 and AIDS.186 Inhibition of
gastric acid secretion with either H2 receptor antagonists or
proton pump inhibitors can result in marked increases in
gastric pH. Although gastric pH can be considerably elevated
in response to histamine H2 antagonist therapy, there are
usually periods between doses where gastric pH may be
relatively acidic. In contrast, omeprazole therapy can com-
pletely inhibit acid secretion on a round-the-clock basis.187
Temporal Pattern of Gastric and Duodenal pH after
MealssAfter ingestion of a meal, gastric acid secretion
promptly increases above basal rates such that within 90 min
after ingestion, the rates of acid secretion approach maximal
capacity. Average acid secretion after a meal range between
Table 4sCompilation of Regional Intestinal pH Values in Healthy Human
Subjects in Pre- or Postprandial States a
Intestinal Site Preprandial pH
Postprandial pH
(time after meal ingestion)
Duodenum 4.0 − 5.4 4.9 − 5.9 (0−240 min)
5.8 − 6.5 5.3 − 6.1 (180−240 min)
6.4 ± 0.6 4.5 − 5.5 (0−60 min)
Jejunum 4.4 − 6.5 5.2 − 6.0 (0−180 min)
6.6 ± 0.5 6.2 ± 0.2 (0−60 min)
Ileum 6.8 − 8.0 6.8 − 7.8
7.4 ± 0.4 6.8 − 8.4
a Values are means ± SD or pH range (from ref 180).
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20 and 30 mmoL/h, with values for men typically being a little
higher than for women.188-190 Total postprandial pancreatic
output is ∼60-70% of the output attained in response to
maximal stimulation with intravenous infusion of cholecys-
tokinin, resulting in a bicarbonate secretion rate of ∼15-17
mEq/h.191 The secretion of the alkaline pancreatic fluid is
largely regulated by the amount of acid entering the duode-
num. The pH of the alkaline fluid entering the duodenum at
high output rates is ∼8,192 and after mixing with the bile and
alkaline fluids secreted by the mucosal lining of the intestine,
the acidic chyme entering the duodenum is partially neutral-
ized.
After ingestion of a meal, gastric pH is distinctly but briefly
elevated in spite of increased gastric acid secretion, which is
attributed to the diluting and buffering effect of the ingested
food components.159 After gastric emptying occurs, the gastric
pH gradually declines until the fasted-state pH environment
has been reestablished. The decline in gastric pH is a function
of both the ability of the meal to stimulate gastric acid
secretion and the rate at which the meal is emptied from the
stomach.
Few studies have measured gastric pH after ingestion of
relatively normal solid/liquid meals.167,170,193 In one study,
Malagelada et al.167 studied gastric pH in six healthy subjects
by an aspiration technique after ingestion of a meal containing
ground steak, bread, butter, vanilla ice cream with chocolate
syrup, and water (458 Kcal). The pH of the gastric contents
after ingestion of the meal was ∼5.0, reflecting both the
dilution and buffering effects of the meal. Sixty minutes after
meal ingestion, the pH had fallen to <3.0, and after 120 min,
the pH had returned to values of <2.0. In a similar manner,
Dressman et al.170 studied post-prandial gastric pH in 24
young healthy men and women after administration of a meal
containing hamburger, bread, hash brown potatoes, and milk
(1000 Kcal). During the meal, gastric pH increased to a
median value of 5.0 (IQR, 4.3-5.4). The highest recorded pH
value was a peak value of 6.7 (IQR, 6.4-7.0) that occurred
within the first 5 min of eating. By constantly monitoring
gastric pH values, it was possible to determine the time course
of the reestablishment of gastric pH, and it took 11 ( 10 min
to return to pH 5, 28 ( 24 min to return to pH 4, 56 ( 41 min
to return to pH 3, and 107 ( 70 min to return to pH 2. Similar
profiles were observed in healthy elderly subjects for whom
the median pH during the meal was 4.9 (IQR, 3.9-5.5), with
a peak pH value of 6.2 (5.8-6.7).185 However, the time
required for gastric pH to return to 2.0 was significantly longer
when compared with the younger subjects.
There is considerable variability in the pH of the duodenal
bulb in the first 60-min period after ingestion of a meal, with
values ranging between 3.8 and 6.1.171-174 Typically, the pH
of the duodenal bulb has returned to fasting pH values within
3 h of meal ingestion. There is less data available about the
postprandial pH in the mid-to-distal region of the duode-
num.167,170,174 Dressman et al.170 noted that during ingestion
of a standard solid-liquid meal by young healthy subjects, the
overall median pH of the mid-to-distal portion of the duode-
num was 6.3 (IQR, 6.0-6.7) and the overall post-prandial
median pH over a period of 4 h was 5.4 (IQR, 5.0 to 5.7).
Comparatively, in healthy elderly subjects, the overall median
pH during meal ingestion was 6.5 (IQR, 6.4-6.7) and the
overall postprandial median pH was 5.6 (IQR, 5.1-6.0). These
data indicate that a brief period of elevated duodenal pH
occurs upon ingestion of the meal that can be attributed to
the cephalic phase of pancreatic bicarbonate secretion.194
When considered in an overall context, the pH in the post-
prandial phase in the duodenum is lower than that in the
fasted state.
Few studies have reported the pH of the jejunum in the
fed state. In one study where a Lundh test meal (dried milk,
vegetable oil, and dextrose) was administered to healthy
subjects, the pH of the proximal jejunum increased to 6.5 at
30 min after meal ingestion and then decreased to 5.7 at 3 h
after ingestion.174 Similarly, Temple et al.195 reported that
the jejunal pH was 5.9 at 30 min after ingestion of a test meal
and also decreased to a value of 4.7 at 2 h after ingestion.
The pH of the ileum in the fed state has not been studied.
Impact of Differences in Pre- and Postprandial GI
pH on Bioavailability
The rate of dissolution, chemical stability, and intrinsic
permeability of a drug may be affected by temporal changes
in GI pH. In the following sections we primarily address the
role of the changing GI pH environment on the intrinsic
factors related to drug absorption, rather than the pH
dependence of the various extrinsic formulation-related fac-
tors.
Drug Solubility and DissolutionsThe pH differences in
the contents of the upper GI tract between fed and fasted
states can influence the dissolution and absorption of weakly
acidic and basic drugs. The dissolution rate of weak bases is
typically greater in gastric fluids than in the intestine in the
fasted state, whereas that of weak acids is at a minimum in
the stomach and increases as undissolved drug is transported
to the less acidic regions of the intestine. Therefore, elevation
of gastric pH following a meal may enhance the dissolution
of a weak acid in the stomach but inhibit that of a weak base.
Furthermore, because food inhibits the rate of gastric empty-
ing,159 prolonged retention in the stomach may increase the
proportion of drug that dissolves prior to passage into the
small intestine. The primary site of drug absorption is usually
the small intestine because of its greater mucosal surface area
and range of transport mechanisms, so the class of drugs most
vulnerable to pH-related changes in postprandial absorption
are poorly water-soluble weak bases.
Drug ReleasesThe disintegration and dissolution of some
coating materials used on tablets may be pH dependent,
thereby affecting drug release. Examples of such polymers
include, among others, shellac, polyvinylacetal diethylami-
noacetate, and amphoteric polyvinylpyridine derivatives. For
example, pH-dependent disintegration of the water-proof
coating of sugar-coated tablets of chloramphenical and met-
ronidazole led to reduced bioavailability in subjects with
elevated gastric pH.196,197 Modern enteric coatings, such as
cellulose acetate phthalate, polyvinylacetate phthalate, and
the polymethacrylates, rely on their pH-solubility profiles to
provide enteric protection. These coatings are virtually
insoluble at acid pH but begin to dissolve rapidly at charac-
teristic pH values between 4.5 and 8 (depending on the
polymer backbone, degree of substitution, and the pKa of the
substituent species). The pH sensitivity of coating-dissolution
profiles suggests that small alterations in GI pH could
significantly affect formulation performance because higher
than normal gastric pH could result in premature release of
drug in the stomach, and lower than normal intestinal pH
values could retard drug release with the potential for
compromising bioavailability.198 For example, Qureshi et
al.199 found that the Tmax (time to maximum concentration)
from enteric-coated ketoprofen tablets was shorter and the
Cmax (maximum concentration) was higher in subjects pre-
treated with omeprazole (to elevate the gastric pH) compared
with control subjects; these results are consistent with initial
drug release in the stomach.
Changing GI pH values may also impact on the perme-
ability of insoluble film coatings used to provide controlled
release of medicaments as well as on the overall dissolution
and drug release patterns from various matrix-based sustained-
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release formulations. For example, the release of ephedrine
and amphetamine from a peroral depot polystyrene ion-
exchange resin was high when in the stomach, but decreased
during transit through the small intestine.200 Changing
solution pH values influences the liberation of drugs embed-
ded in slowly eroding FA-based wax matrices (e.g., butyl
stearate, saccharose monostearate, glycerin monostearate) by
affecting the hydrolysis rate of FA esters.200 Kohri et al.201
evaluated the effect of gastric pH on the bioavailability of
dipyridamole from pH-dependent sustained-release granules
(drug release decreased with increasing pH). When admin-
istered to gastric acidity-controlled rabbits, a 5-fold decrease
in Cmax and a fourfold decrease in AUC (area under the curve
of concentration versus time) was observed in the group with
low gastric acidity compared with the group with high gastric
acidity.
Formulation excipients can also cause drug release to vary
with pH. For example, various calcium salts are used as
diluents or disintegrants in solid dosage forms, and these salts
dissolve in gastric fluids via reaction with hydrochloric acid.
The solubility of dicalcium and tricalcium phosphate is
decreased 10-fold when the solution pH is increased from 1.0
to 2.0.202 Therefore, rapid disintegration of tablets containing
these excipients only occurs under acidic conditions. A pH-
dependent interaction of weak bases with the disintegrant
croscarmellose sodium has been described (interaction in-
creased with increasing pH),203 leading to the suggestion that
the bioavailability of such formulations may be compromised
at elevated pH. In terms of soft gelatin capsules, shell
dissolution is dependent on pH as evidenced by the reported
dissolution rate decrease of about 2-3-fold as pH was in-
creased from 1.0 to 3.0 (after pH 3.0, the rate was essentially
pH independent).204
Drug StabilitysThe stability of acid-labile drugs is a
major consideration when interpreting oral bioavailability
profiles under conditions of potentially varied pH. Elevated
gastric pH may afford enhanced bioavailability of acid-labile
drugs such as penicillin, erythromycin, and digoxin. For
example, under acidic conditions, digoxin is hydrolyzed to the
digoxigenin aglycone derivative, which has reduced pharma-
codynamic activity. In a recent bioavailability study, Cohen
et al.205 found that pentagastrin (which increases gastric acid
secretion) reduced the urinary excretion of unchanged digoxin
from 34 to 21% of the administered dose, whereas, omeprazole
(which reduces gastric acidity) increased urinary excretion to
47% of the administered dose.
Intestinal PermeabilitysFor ionic drugs, the fraction of
drug available for absorption may be altered by changing pH
values. Because drugs absorbed by a passive, transcellular
mechanism are predominantly absorbed in their un-ionized
form, the pH in the intestinal lumen relative to the pKa of
the drug is an important determinant of the absorption rate.
According to the pH-partition theory,206 a weak base would
be best absorbed at pH values above the pKa, whereas a weak
acid would be best absorbed at pH values below the pKa,
providing there are no solubility limitations. Therefore, the
half-maximal rate of absorption occurs at pH values close to
their pKa. In such cases, Winne207 demonstrated that the
following equation (depending on whether the compound is
an acid or base) can describe the absorption profile of
sufficiently lipophilic drugs.
where Pm is the membrane permeability, and Paq the aqueous
boundary layer permeability (as a first approximation, Pm/
Paq can be represented by the octanol/water partition coef-
ficient). For drugs with half-maximal pH absorption data in
the range of small intestinal pH values, the absorption rate
would be expected to be sensitive to small shifts in intestinal
pH (with up to a 10-fold change in rate with a one unit shift
in pH). Furthermore, if a drug is incompletely and variably
absorbed, then minor changes in lumenal pH would be
expected to result in changes in the rate and extent of
absorption. Examples of such compounds include some
diuretics, antibacterial agents used to treat urinary tract
infections, and various nonsteroidal antiinflammatory com-
pounds.
The effect of lumenal pH on intestinal permeability has
been documented for several drugs for which there are
solubility limitations to absorption,207-210 with intestinal
permeability being directly related to the rate of absorption.209
For drugs that are incompletely absorbed, altered perme-
ability resulting from a change in intestinal pH would be
expected to translate into an alteration in the rate of absorp-
tion. Drugs with pH-dependent permeability include aspi-
rin,211 R-methyl dopa,212 and cimetidine.213 For example, data
from intestinal perfusions conducted in humans indicated that
the effective permeability of R-methyl dopa was maximal at
pH 6.0 and decreased as the pH of the perfusion medium was
either decreased to pH 4.5 or increased to pH 7.4.
Case Studies: Effect of Changing GI pH on Drug
Absorption
It is important that poorly water-soluble weakly basic drugs
dissolve rapidly in the stomach because dissolution of undis-
solved drug in the intestine may be too low to permit complete
absorption. Ketoconazole is a weak dibasic drug (pKa1 ) 6.51,
pKa2 ) 2.94) that exhibits pH-dependent dissolution. At pH
values of <3, in vitro dissolution was rapid, with >85%
dissolved within 5 min, whereas at pH 6, only 10% dissolved
after 1 h.214 Consequently, absorption of ketoconazole would
be expected to be influenced by those factors that affect gastric
acidity. Piscitelli et al.215 determined that when ranitidine
was administered concomitantly with ketoconazole to titrate
gastric pH to 6.0, the mean plasma AUC0-12 h values de-
creased to 1.6 µg h/mL from 37.1 µg h/mL, and mean Cmax
values were correspondingly reduced from 8.2 to 0.6 µg/mL.
Similar results were also observed when cimetidine was
employed to raise gastric pH during concomitant ketoconazole
therapy.216 Plasma concentration-time profiles of ketocona-
zole when administered to fasting or fed subjects, after pre-
treatment with glutamic acid, after pre-treatment with cime-
tidine and bicarbonate to induce a simulated achlorhydria,
or after pre-treatment with glutamic acid in the simulated
achlorhydric state are shown in Figure 2.217 The marked
changes in the plasma profiles are readily interpreted in the
context of the expected solubility of the weakly basic drug in
the gastric environment under these different treatment
regimens.
Ogata et al.218 investigated the bioavailability of cinnarizine
in subjects with low and high gastric acidity. Cinnarizine is
a weak base that readily dissolves at pH 1, although the
solubility is <10 µg/mL at pH values >5. The maximum
plasma concentration and plasma AUC data for cinnarizine
decreased by almost 85% in subjects with elevated gastric pH
compared with those exhibiting low gastric acidity.
Lebsack et al.219 evaluated the effect of gastric acidity on
the oral absorption of enoxacin, which is a quinolone antibi-
otic. Coadministration of ranitidine significantly decreased
the mean enoxacin plasma Cmax by 45% and the AUC values
by 32%, whereas this effect was abolished when pentagastrin
was used to maintain a low gastric pH environment. Enoxa-
cin is very soluble in solutions with pH values of <4.5 to 5,
above which the solubility decreases to <0.5 mg/mL due to
its amphoteric nature. In a clinical study in which ranitidine
pH (max/2) ) pKa ( log (1 + Pm/Paq)
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was administered to increase gastric pH above 5, the observed
decrease in bioavailability may have been due to the decreased
solubility of enoxacin at higher pH values.
Cefpodoxime proxetil is an oral cephem antibiotic that also
exhibits pH-dependent dissolution. For example, the solubil-
ity of cefpodoxime proxetil in aqueous solutions is reduced
from ∼11 mg/mL at acidic pH to ∼0.4 mg/mL at near neutral
pH. When subjects were treated with 40 mg of famotidine 1
h prior to administration of cefpodoxime proxetil, the mean
peak plasma levels were reduced by 48% from 2.5 to 1.3 µg/
mL, and there was a similar decrease in the plasma AUC
values from 14.0 to 8.4 µg h/mL.220
Diazepam is an example of a drug for which the rate, rather
than the extent of absorption is affected by gastric pH.
Diazepam is a weak base with solubilities of 13.4 mg/mL at
pH 1 and 50 µg/mL at pH 7. In a clinical study conducted in
healthy subjects, the maximum plasma concentration of
diazepam was reduced by 50% in subjects with high gastric
pH values compared with those with a low gastric pH,
although there was not a corresponding decrease in the
plasma AUC values.221
Dipyridamole (pKa 6.4) has an aqueous solubility of 5 µg/
mL at pH 7.0 that increases to 29 mg/mL at pH 2.5. Russell
et al.222 found that when famotidine was administered con-
comitantly with dipyridamole to elevate gastric pH above 5.0,
the plasma Cmax of dipyridamole was reduced by 79% when
compared to control and the mean plasma AUC0-36 h values
were reduced by 37%.
The absorption of inorganic salts are also sensitive to GI
pH profiles. For example, calcium salts, which are often used
in the treatment of osteoporosis in elderly women, are
relatively insoluble and depend on an acidic pH for dissolution.
Recker223 found that the average fractional absorption of
calcium, from a dose of calcium carbonate, was 0.047 in
achlorhydric subjects compared with 0.225 in control subjects.
The absorption of several trace elements, such as iron, zinc,
and copper, also appears to depend on gastric acid for complete
dissolution.184 Henderson et al.224 found that the mean
plasma zinc AUC values from a dose of zinc acetate was
reduced from 524 µg h/dL in subjects with low gastric pH (pH
<3) to 378 µg h/dL when 40 mg of famotidine was adminis-
tered prior to zinc administration, which maintained gastric
pH above 5.0. When administered as zinc oxide, the zinc
plasma AUC was reduced 82% in subjects with elevated
gastric pH. The effect of gastric pH on the resulting plasma
concentrations of zinc after administration of either zinc
acetate or zinc oxide to subjects with low or high gastric pH
is shown in Figure 3. In vitro studies verified the importance
of a low pH value for facilitating the dissolution of these
different zinc salts.
From the studies just described, gastric pH appears to be a
primary determinant of absorption when drug dissolution is
pH dependent and the solubility of the drug at higher pH
values is poor. As described, the pH of gastric fluids is
typically elevated above 3 (and to values as high as 5), during
the first 60-90 min after ingestion of a meal. Consequently,
if a poorly water-soluble, weakly basic drug is administered
postprandially, dissolution in the stomach may be decreased
and its subsequent absorption impaired due to periods of
elevated gastric pH. However, if the particular drug is
relatively lipophilic, these potentially limiting effects of pH
may be offset by bile-mediated dissolution and increased
residence time in the upper GI tract.
Predictive Approaches to Assessing pH-Dependent
Bioavailability
Dissolution tests are a simple and ready means for char-
acterizing the pH-dependency of drug release and dissolution.
In vitro dissolution tests should be conducted over the range
of pH values that encompass the different GI pH profiles
typically observed in fasted and fed states. Confirmatory
clinical studies are often conducted if the solubility and
dissolution profile of a drug indicates that postprandial
absorption and bioavailability may be sensitive to the antici-
pated changes in GI pH values.
Clinical StudiessClinical studies in humans offer a useful
means to investigate the effect of gastric pH on drug absorp-
tion with either H2-receptor antagonists, proton pump inhibi-
tors, or antacids to raise gastric pH. Oral or intravenous
cimetidine can effectively lower basal gastric acid secretion
for periods of at least 5 h,225,226 and meal-stimulated secretion
of acid for periods of 3 to 4 h in healthy subjects.227,228
However, a drawback associated with the use of cimetidine
to diagnostically evaluate the effect of gastric pH on bioavail-
ability is its potential to inhibit the oxidative metabolism of
Figure 2sMean plasma ketoconazole concentration versus time profiles after
oral administration of 200 mg of ketoconazole to subjects in either a fasted state
(0−0), a fed state (9−9), after pretreatment with 680 mg of glutamic acid
hydrochloride (2−2), in a simulated achlorhydric state induced with cimetidine
and bicarbonate (O−O), or after pretreatment with 680 mg of glutamic acid
hydrochloride in the simulated achlorhydric state (b−b). (Adapted from ref 217).
Figure 3sPlasma concentrations of zinc after administration of zinc acetate to
subjects with low gastric pH (0−0) or high gastric pH (9−9), and after
administration of zinc oxide to subjects with low gastric pH (4−4) or high gastric
pH (2−2), in a crossover study conducted in fasted healthy subjects. (Adapted
from ref 224).
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some drugs via interaction with the cytochrome P-450
system.229-231 Ranitidine is ∼10-12 times more potent than
cimetidine in inhibiting gastric acid secretion in humans,232,233
but famotidine is reported to be 20 times more potent than
cimetidine on a molar basis.234 An oral dose of 300 mg of
ranitidine is sufficient to increase 24 h median gastric pH
values from 1.3 to 4.0 in humans,235 and produce an overall
70% reduction in acid secretion.236 Oral administration of a
suspension of 40 mg of famotidine can elevate gastric pH
above 5.0 for at least 2-3 h after administration.224 In terms
of effects on cytochrome P-450, ranitidine is reported to be
much less active than cimetidine,237,238 although famotidine
does not appear to have any effect at therapeutic doses.239,240
However, ranitidine has been reported to either accel-
erate,241-243 have no effect,244,245 or delay gastric emptying in
humans.246,247 Cimetidine241,246,247 and famotidine243,248 have
no effect on the rate of gastric emptying in humans. Proton
pump inhibitors, such as omeprazole and lansoprazole, can
effectively elevate gastric pH above 4.0 on a round-the-clock
basis.249-251 However, omeprazole has been reported to inhibit
oxidative metabolism,252-254 but it has no effect on the rate of
gastric emptying.255,256
The use of antacids containing calcium, aluminum, or
magnesium to study the effect of pH on absorption should be
undertaken with caution because drugs such as tetracy-
cline85,257 and the quinolone antibiotics258 form nonabsorbable
chelates with the metal ions. Aluminum hydroxide gel has
been found to delay gastric emptying in humans.259,260 Sodium
bicarbonate is often employed to neutralize gastric acidity as
it does not form chelates with drugs and it has no effect on
gastric emptying.261
The use of concomitant drug therapy to evaluate the effect
of gastric pH on drug bioavailability is a well-accepted
practice. However, care must be taken to ensure that the
agent employed to modulate gastric pH does not alter other
factors affecting drug bioavailability. Whenever these studies
are undertaken, gastric pH should be continuously monitored
in control and treated subjects because intragastric pH may
fluctuate widely over time, and there is inherent variability
in individual responses to proton pump inhibitors and H2
receptor antagonists.262,263
Conclusions and Perspectives
The effect of food on the absorption of coadministered drugs
has often been assessed in a largely phenomenological man-
ner. The combined effects of slowed gastric emptying and the
potential for binding to food components has typically been
assumed to reduce, or at least slow drug absorption. In many
cases, and particularly for water-soluble drugs with high
bioavailability, this is indeed the situation. However, for
drugs with either pH-dependent solubility or poor aqueous
solubility, postprandial alterations in GI pH and the enhanced
solubilizing capacity of the GI tract have the potential to
significantly impact on drug absorption.
Changes in postprandial gastric physiology are primarily
defined by a slowing of gastric emptying and a marked rise
in pH. These effects impact primarily on gastric dissolution,
with the magnitude of effect being dependent on the pKa and
solubility of the drug. The transient rise in gastric pH is of
most importance when assessing the postprandial dissolution
of weak bases.
In the small intestine, coadministration of food and/or lipids
leads to secretion of bile and digestive enzymes that produce
a complex system of intestinal colloidal phases designed to
facilitate the digestion and absorption of dietary lipids. The
increased concentration of bile and the presence of bile salt/
dietary lipid mixed micelles can improve the wetting of poorly
soluble drugs and increase their effective solubility via solu-
bilization. Postprandial absorption may be improved by direct
permeability enhancement due to FA and MG, or by solubi-
lization that facilitates transport of lipophilic drugs across the
aqueous diffusion layer. Intestinal lymphatic transport may
also contribute to the absorption of highly lipophilic drugs.
Appreciation of the physicochemical basis for enhanced
postprandial bioavailability can be prospectively used to
design and optimize drug formulations and dosing strategies.
Drugs or dosage forms that show poor dissolution or release
rates at higher pH values should be administered in the fasted
state. If it is necessary to administer such drugs in the fed
state (e.g., those which cause gastric irritation in the fasted
state), then they could be coadministered with drinks such
as fruit juices or carbonated beverages that buffer gastric pH
to lower values. Because of the inherent variability associated
with gastric pH in the preprandial state, consideration could
also be given to coadministration of a suitable drink with
drugs for which dissolution is highly pH dependent.
Two variables affecting dissolution that can be controlled
by formulation are surface area and solubility. For example,
particle size can be reduced to increase the effective surface
area available for dissolution, and the solubility of weak acids
or bases can be modified by buffering the surrounding
“microenvironment”. However, use of buffering agents is often
limited by differences in solubility between the buffer and the
drug such that their relative rates of dissolution preclude
maintenance of the microenvironment during the period of
dissolution.
The challenge is to identify the potential physicochemical
basis for food-enhanced bioavailability of particular drugs and
use it as a starting point to prospectively develop better oral
formulations.
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